Annals of Oncology

What is the impact of sentinel node biopsy in the management of cancer?
pp. 1217-1218(2)
Author: Lejeune, F. J.

Treatment of advanced breast cancer: the good, the bad and the ugly
pp. 1219-1221(3)
Authors: Colleoni, M.; Gelber, S.; Goldhirsch, A.

Myeloma bone disease: pathophysiology and management
pp. 1223-1231(9)
Authors: Terpos, E.; Dimopoulos, M.-A.

Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?
pp. 1232-1236(5)
Authors: Copie-Bergman, C.; Locher, C.; Levy, M.; Chaumette, M. T.; Haioun, C.; Delfau-Larue, M. H.; Leroy, K.; Gaulard, P.; Delchier, J. C.

Sentinel node biopsy is reliable in early-stage cervical cancer but not in locally advanced disease
pp. 1237-1242(6)
Authors: Barranger, E.; Coutant, C.; Cortez, A.; Uzan, S.; Darai, E.

Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
pp. 1243-1252(10)
Authors: Bocci, G.; Tuccori, M.; Emmenegger, U.; Liguori, V.; Falcone, A.; Kerbel, R. S.; Del Tacca, M.

Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and <it>PEA3</it>-mediated transcriptional repression of Her2/<it>neu</it> (<it>erb</it>B-2) oncogene
pp. 1253-1267(15)
Authors: Menendez, J. A.; Vellon, L.; Lupu, R.

A 2-month cisplatin–epirubicin–paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study
pp. 1268-1275(8)
Authors: Frasci, G.; D'Aiuto, G.; Comella, P.; Thomas, R.; Botti, G.; Di Bonito, M.; D'Aiuto, M.; Romano, G.; Rubulotta, M. R.; Comella, G.; On behalf of the Southern Italy Cooperative Oncology Group SICOG Italy,

Adjuvant chemotherapy for elderly patients (70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients<cross-ref type="fn" refid="fn1">†</cross-ref>
pp. 1276-1282(7)
Authors: Brunello, A.; Basso, U.; Pogliani, C.; Jirillo, A.; Ghiotto, C.; Koussis, H.; Lumachi, F.; Iacobone, M.; Vamvakas, L.; Monfardini, S.

Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients
pp. 1283-1288(6)
Authors: Vanhuyse, M.; Fournier, C.; Bonneterre, J.

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
pp. 1289-1296(8)
Authors: Hennessy, B. T.; Gauthier, A. M.; Michaud, L. B.; Hortobagyi, G.; Valero, V.

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
pp. 1297-1304(8)
Authors: Gradishar, W. J.; Wedam, S. B.; Erban, J.; Limentani, S. A.; Tsai, K.-T.; Olsen, S. R.; Swain, S. M.

Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer
pp. 1305-1310(6)
Authors: Negri, F. V.; Wotherspoon, A.; Cunningham, D.; Norman, A. R.; Chong, G.; Ross, P. J.

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
pp. 1311-1319(9)
Authors: Folprecht, G.; Grothey, A.; Alberts, S.; Raab, H.-R.; Köhne, C.-H.

Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus
pp. 1320-1325(6)
Authors: Mauer, A. M.; Kraut, E. H.; Krauss, S. A.; Ansari, R. H.; Kasza, K.; Szeto, L.; for the University of Chicago Phase II Network,

Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO
pp. 1326-1333(8)
Authors: Kollmannsberger, C.; Budach, W.; Stahl, M.; Schleucher, N.; Hehr, T.; Wilke, H.; Schleicher, J.; Vanhoefer, U.; Jehle, E. C.; Oechsle, K.; Trarbach, T.; Boehlke, I.; Kanz, L.; Hartmann, J. T.; Bokemeyer, C.

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
pp. 1334-1342(9)
Authors: Zhang, X.-T.; Li, L.-Y.; Mu, X.-L.; Cui, Q.-C.; Chang, X.-Y.; Song, W.; Wang, S.-L.; Wang, M.-Z.; Zhong, W.; Zhang, L.

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
pp. 1343-1351(9)
Authors: Campone, M.; Roché, H.; Kerbrat, P.; Bonneterre, J.; Romestaing, P.; Fargeot, P.; Namer, M.; Monnier, A.; Montcuquet, P.; Goudier, M.-J.; On behalf of the FASG French Adjuvant Study Group France,

Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
pp. 1352-1358(7)
Authors: Monfardini, S.; Aversa, S. M. L.; Zoli, V.; Salvagno, L.; Bianco, A.; Bordonaro, R.; Benevolo, G.; Crugnola, M.; Crivellari, G.; Vivaldi, P.; Basso, U.; On behalf of the Non-Hodgkin's Lymphoma Cooperative Study Group NHLCSG,

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study
pp. 1359-1365(7)
Authors: Josting, A.; Sieniawski, M.; Glossmann, J.-P.; Staak, O.; Nogova, L.; Peters, N.; Mapara, M.; Dörken, B.; Ko, Y.; Metzner, B.; Kisro, J.; Diehl, V.; Engert, A.

Pretreatment prognostic factors and treatment outcome in elderly patients with <it>de novo</it> acute myeloid leukemia
pp. 1366-1373(8)
Authors: Chen, C.-C.; Yang, C.-F.; Yang, M.-H.; Lee, K.-D.; Kwang, W.-K.; You, J.-Y.; Yu, Y.-B.; Ho, C.-H.; Tzeng, C.-H.; Chau, W.-K.; Hsu, H.-C.; Gau, J.-P.

Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
pp. 1374-1380(7)
Authors: Bajetta, E.; Catena, L.; Procopio, G.; Bichisao, E.; Ferrari, L.; Della Torre, S.; De Dosso, S.; Iacobelli, S.; Buzzoni, R.; Mariani, L.; Rosai, J.

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology
pp. 1381-1390(10)
Authors: Krüger, W. H.; Bohlius, J.; Cornely, O. A.; Einsele, H.; Hebart, H.; Massenkeil, G.; Schüttrumpf, S.; Silling, G.; Ullmann, A. J.; Waldschmidt, D. T.; Wolf, H.-H.

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
pp. 1391-1397(7)
Authors: Holden, S. N.; Eckhardt, S. G.; Basser, R.; de Boer, R.; Rischin, D.; Green, M.; Rosenthal, M. A.; Wheeler, C.; Barge, A.; Hurwitz, H. I.

Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy
pp. 1399-1399(1)
Author: Ghesquieres, H.

Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation
pp. 1400-1400(1)
Authors: Shimada, H.; Shima, H.; Shimasaki, N.; Yoshihara, H.; Mori, T.; Takahashi, T.

Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone
pp. 1401-1402(2)
Authors: Park, Y. H.; Kim, S.; Choi, S.-J.; Ryoo, B.-Y.; Yang, S. H.; Cheon, G. J.; Choi, C.-W.; Lim, S. M.; Yoo, J. Y.; Lee, S.-S.

Reply to the Letter to the Editor on “Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients”, by I. Cohen Ann Oncol 2005; 16: 1399
pp. 1402-1403(2)
Authors: Paridaens, R.; Morales, L.; Neven, P.; On behalf of all co-authors of the original article,

Response to “Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients”, by L. Morales et al. (Ann Oncol 2005; 16: 70–74)
pp. 1402-1402(1)
Author: Cohen, I.

Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?
pp. 1403-1404(2)
Authors: Ferretti, G.; Mandalà, M.; Bria, E.; Papaldo, P.; Carlini, P.; Fabi, A.; Milella, M.; Ruggeri, E. M.; Nisticò, C.; Cognetti, F.